This study aims to test a new drug, AZD2373, for people with a specific kidney disease called APOL1-Mediated Kidney Disease (AMKD). AMKD affects the kidneys and can cause damage over time. Participants need to have a specific genetic condition linked to AMKD, known as high-risk APOL1 genotypes (G1 and G2). The study will compare the results of AZD2373 to a placebo, which is a substance with no active drug, to check if AZD2373 can help reduce kidney damage, measured by a test called UACR (Urine Albumin to Creatinine Ratio).
This is a Phase 2b study, meaning it is in an early stage to see if the drug is safe and works well. Participants will be part of the study for at least 30 weeks. Around 96 people will join, with about 32 in each group. They will be randomly assigned to either the drug or placebo.
**Key Points:** - **Study Duration**: The study lasts for a minimum of 30 weeks. - **Eligibility**: Ages 18-65 with specific genetic markers, no dialysis or organ transplants. - **Exclusions**: Conditions like Type 1 diabetes, very high BMI, or certain heart issues.Participation involves regular check-ups to monitor safety and results.